

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Michael Young et al.                      Art Unit :  
Serial No. :    Examiner :  
Filed : February 20, 2002  
Title : ERYTHROPOIETIN ANALOG-HUMAN SERUM ALBUMIN FUSION

Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the specification:

Insert the following paragraph at page 1, line 6:

-- This application is a divisional of U.S. Serial Number 09/333,213, filed June 15, 1999, which claims priority to U.S. Serial Number 06/089,343, filed June 15, 1998, the contents of which are incorporated herein by reference. --

In the claims:

Cancel claims 27 – 45, 48-50, and 53-55.


Amend claim 52 as follows:

-- 52. (Amended) The erythropoietin analog of claim 51 wherein the EPOa is Gln24, Gln38, Gln83, Alal26 EPO. --

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL486016505US

I hereby certify under 37 CFR §1.10 that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office to Addressee with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit February 20, 2002  
Signature   
Leroy Jenkins  
Typed or Printed Name of Person Signing Certificate

Applicant : Michael Young et al.  
Serial No. :  
Filed : February 20, 2002  
Page : 2

Attorney's Docket No.: 10275-041002 / TCI-040-1 DIV


REMARKS

Attached is a marked-up version of the changes being made by the current amendment.

Applicant asks that all claims be examined. Please apply any other charges or credits to  
Deposit Account No. 06-1050.

Respectfully submitted,

Date: 2/20/02

  
Laurie Butler Lawrence  
Reg. No. 46,593

Fish & Richardson P.C.  
225 Franklin Street  
Boston, Massachusetts 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

20392768.doc

20392768.doc

-- 52. (Amended) The erythropoietin analog of claim [48] 51 wherein the EPOa is Gln24, Gln38, Gln83, Alal26 EPO. --